Pyrotinib Plus Vinorelbine Versus Lapatinib Plus Capecitabine in Patients With Previously Treated HER2-Positive Metastatic Breast Cancer: A Multicenter, Retrospective Study

BACKGROUND: Pyrotinib is a newly-developed irreversible pan-ErbB (erythroblastic leukemia viral oncogene homolog) receptor oral tyrosine kinase inhibitor (TKI) with promising efficacy in the human epidermal growth factor receptor-2 (HER2) positive breast cancer. The phase III PHOEBE study proved tha...

Descripción completa

Detalles Bibliográficos
Autores principales: Xie, Yizhao, Li, Yi, Ting, Luo, Sang, Die, Yuan, Peng, Li, Wei, Li, Huihui, Ge, Rui, Wang, Biyun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8374067/
https://www.ncbi.nlm.nih.gov/pubmed/34422652
http://dx.doi.org/10.3389/fonc.2021.699333

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8374067/
https://www.ncbi.nlm.nih.gov/pubmed/34422652
http://dx.doi.org/10.3389/fonc.2021.699333

Ejemplares similares